Neoadjuvant endocrine therapy in breast cancer: a single-institution epidemiological and clinicopathological analysis from southern Brazil
Introduction: Breast cancer accounts for approximately 11.6% of all oncologic diagnoses, with hormone receptor-positive (HR+) and HER2 negative (HER2-) tumors representing a significant proportion of cases. In this context, neoadjuvant endocrine therapy has emerged as a therapeutic alternative, with potential benefits...